The similar benefit (PFS) from TKI and chemotherapy, the comparable OS, and the absence of other clinical, laboratory or molecular disparities between secondary and de novo metastatic EGFR+ NSCLC (Table 1) argue against true biologic differences among them. Here, EGFR is linked to non-small cell lung carcinoma.